Globenewswireยท2025-05-13 17:00Core Viewpoint - Alumis Inc. has received stockholder approval for its merger with ACELYRIN, INC., marking a significant step towards closing the transaction and enhancing its capabilities in developing therapies for immune-mediated diseases [1][2][3] Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies using a precision approach to improve clinical outcomes for patients with immune-mediated diseases [4] - The company utilizes a proprietary precision data analytics platform to build a pipeline of molecules targeting a wide range of immune-mediated diseases, both as monotherapy and combination therapies [4] - Alumis' leading product candidate, ESK-001, is an oral, selective small molecule inhibitor currently being evaluated for moderate-to-severe plaque psoriasis and systemic lupus erythematosus [4] Merger Details - The merger with ACELYRIN is anticipated to close in the second quarter of 2025, pending the fulfillment of customary closing conditions [3] - Martin Babler, President and CEO of Alumis, expressed gratitude to stockholders for their support and emphasized the goal of maximizing the value of their portfolio post-merger [2] Future Prospects - The merger is expected to provide Alumis with a strengthened financial foundation, enabling the advancement of breakthroughs in the treatment of immune-mediated diseases [2]